- Home
- MSB vs DMAC Comparison
MSB vs DMAC Comparison
Compare MSB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- DMAC
- Stock Information
- Founded
- MSB 1961
- DMAC 2000
- Country
- MSB United States
- DMAC United States
- Employees
- MSB N/A
- DMAC N/A
- Industry
- MSB Metal Mining
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- DMAC Health Care
- Exchange
- MSB Nasdaq
- DMAC Nasdaq
- Market Cap
- MSB 320.9M
- DMAC 310.1M
- IPO Year
- MSB N/A
- DMAC N/A
- Fundamental
- Price
- MSB $34.14
- DMAC $7.06
- Analyst Decision
- MSB
- DMAC Strong Buy
- Analyst Count
- MSB 0
- DMAC 3
- Target Price
- MSB N/A
- DMAC $12.33
- AVG Volume (30 Days)
- MSB 37.7K
- DMAC 262.5K
- Earning Date
- MSB 01-01-0001
- DMAC 11-12-2025
- Dividend Yield
- MSB 19.85%
- DMAC N/A
- EPS Growth
- MSB 425.34
- DMAC N/A
- EPS
- MSB 7.07
- DMAC N/A
- Revenue
- MSB $25,011,439.00
- DMAC N/A
- Revenue This Year
- MSB N/A
- DMAC N/A
- Revenue Next Year
- MSB N/A
- DMAC N/A
- P/E Ratio
- MSB $4.83
- DMAC N/A
- Revenue Growth
- MSB 4.81
- DMAC N/A
- 52 Week Low
- MSB $22.24
- DMAC $3.19
- 52 Week High
- MSB $37.00
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- MSB 55.18
- DMAC 57.38
- Support Level
- MSB $35.01
- DMAC $6.64
- Resistance Level
- MSB $36.69
- DMAC $7.13
- Average True Range (ATR)
- MSB 1.63
- DMAC 0.27
- MACD
- MSB 0.08
- DMAC -0.00
- Stochastic Oscillator
- MSB 57.40
- DMAC 77.21
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.